Unlike the AR antagonists, enzalutamide is an enzymatic inhibitor for p450 17A1 (CYP17) capable of irreversibly blocking steroid conversion in the biosynthesis pathway of active androgens in prostatic tumor cells (Li et al., 2016c). Here, CYP17A1 is linked to prostate neoplasm.